A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Fate Therapeutics
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Incyte Corporation
Pfizer
Genentech, Inc.
Revolution Medicines, Inc.
Jacobio Pharmaceuticals Co., Ltd.
PAQ Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Genentech, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Fate Therapeutics
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Fate Therapeutics
NKMAX Co., Ltd.
NKGen Biotech, Inc.
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Merrimack Pharmaceuticals
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Boehringer Ingelheim
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Eli Lilly and Company